Save time, stay current, and earn CE. You can rely on The Rx Consultant to deliver practical
easy-reading updates on drugs & therapy for front-line pharmacists and nurses.

Every Subscription Includes:

Drug Therapy Updates & Reviews
Every article tells you what's new - and gives you a streamlined review
FREE CE
It's information that you can trust - independently researched and written. No drug industry money or influence
Healthcare News
Keeps you up-to date on the news that matters most - so you will have the answers before you are asked
Patient Q&A Summary Pages
Answers common questions and gives you the key counseling points, so you can streamline patient education
Quick Reference Cards
It's just what you need when you want to check your facts, verify a dose, or give a quick answer.

Untitled Document

News:

Statins for Healthy People?

An international, manufacturer sponsored study of rosuvastatin (Crestor^®) called JUPITER is making headlines. Nearly 18,000 healthy men and women who did not have high cholesterol, but did have elevated levels of high-sensitivity C-reactive protein (CRP), took rosuvastatin 20 mg or a placebo daily for nearly 2 years. High-sensitivity CRP is a protein linked to inflammation. Inflammation plays a role in cholesterol-linked narrowing of arteries and plaque formation... Continue

An Excerpt From The December Edition:

New Considerations for the Treatment of Diabetes in 2008

The development of type 2 diabetes mellitus (T2DM) involves three different mechanisms: insulin resistance, impaired insulin secretion, and excess production of glucose from the liver. Researchers are constantly seeking new drug therapy targets, and less invasive, more convenient routes of drug administration. As treatment for T2DM becomes more complicated and more clinical experience is gained with the drugs currently available, new issues and considerations inevitably arise. Whether these issues involve new insight into possible drug side effects, changes in glycemic treatment goals, or new thoughts involving our monitoring paradigms, it is in your best interest and your patients’ best interest to stay up-to-date.

This article summarizes 6 recent developments in the treatment of T2DM: the link between thiazolidinediones (e.g., Avandia^®, Actos^®) and bone fracture, the potential for heart attacks and heart failure associated with thiazolidinedione use, recent findings regarding tight glucose control and cardiovascular risk, the potential link between inhaled insulin (Exubera^®) and lung cancer, use of the lipid-lowering drug colesevelam (WelCholTM) in patients with T2DM, and the potential benefits and drawbacks of self-monitoring of blood glucose (SMBG) in patients who are not using insulin. Each topic is accompanied by patient discussion points to aid you in your efforts to guide them through these recent developments.